Linking PRMT5 to breast cancer stem cells: New therapeutic opportunities?

被引：11
|
作者：
Chiang, Kelly [1 ]
Davies, Clare C. [1 ]
机构：
[1] Univ Birmingham, Coll Med & Dent Sci, Inst Canc & Genom Sci, Birmingham, W Midlands, England
来源：
MOLECULAR & CELLULAR ONCOLOGY | 2018年 / 5卷 / 03期
基金：
英国医学研究理事会;
关键词：
PRMT5; breast cancer stem cells; epigenetics; arginine methylation; FOXP1;
D O I：
10.1080/23723556.2018.1441628
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The arginine methyitransferase PRMT5 has been increasingly associated with cancer development. Here we describe our recent findings that PRMT5 is a critical regulator of breast cancer stem cell survival via the epigenetic regulation of FOXP1. Consequently, PRMT5 inhibitors could potentially eradicate cancer stem cells thereby preventing tumour relapse.
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Role of PRMT5 in bladder cancer: a comprehensive study
    Ma, Yingxin
    Zhong, Yucheng
    Huang, Weiren
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 (02) : 491 - 498
  • [42] Decreased expression of PRMT5 is associated with prostate cancer
    Guo, CC
    Zhang, X
    Yee, H
    Chiriboga, L
    Melamed, J
    Lee, P
    MODERN PATHOLOGY, 2005, 18 : 143A - 143A
  • [43] PRMT5 inhibition modulates murine dendritic cells activation by inhibiting the metabolism switch: a new therapeutic target in periodontitis
    Mi, Wenxiang
    Qiao, Shichong
    Zhang, Xiaomeng
    Wu, Dongle
    Zhou, Linyi
    Lai, Hongchang
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (09)
  • [44] Role of PRMT5 in neuroendocrine prostate cancer development
    Nam, Hye Seung
    Deng, Xuehong
    Hu, Chang-Deng
    CANCER RESEARCH, 2024, 84 (06)
  • [45] Decreased expression of PRMT5 is associated with prostate cancer
    Guo, CC
    Zhang, X
    Yee, H
    Chiriboga, L
    Melamed, J
    Lee, P
    LABORATORY INVESTIGATION, 2005, 85 : 143A - 143A
  • [46] PRMT5 Is A New Epigenetic Regulator In Cardiovascular Disease
    Merkel, Tobias S.
    Hassel, David
    Krueger, Marcus
    Weichenhan, Dieter
    Plass, Christoph
    Backs, Johannes
    CIRCULATION RESEARCH, 2013, 113 (04)
  • [47] PRMT5 is a Poor Prognostic Marker for NSCLC and Inhibition of PRMT5 Results in Increased Lung Cancer Sensitivity to Cisplatin and Radiotherapy
    Welliver, Meng
    Jin, Feng
    Otterson, Gregory
    Carbone, David
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S844 - S844
  • [48] PRMT5 Is a Critical Regulator of Breast Cancer Stem Cell Function via Histone Methylation and FOXP1 Expression
    Chiang, Kelly
    Zielinska, Agnieszka E.
    Shaaban, Abeer M.
    Sanchez-Bailon, Maria Pilar
    Jarrold, James
    Clarke, Thomas L.
    Zhang, Jingxian
    Francis, Adele
    Jones, Louise J.
    Smith, Sally
    Barbash, Olena
    Guccione, Ernesto
    Farnie, Gillian
    Smalley, Matthew J.
    Davies, Clare C.
    CELL REPORTS, 2017, 21 (12): : 3498 - 3513
  • [49] Breast Cancer Stem Cells as Drivers of Tumor Chemoresistance, Dormancy and Relapse: New Challenges and Therapeutic Opportunities
    De Angelis, Maria Laura
    Francescangeli, Federica
    Zeuner, Ann
    CANCERS, 2019, 11 (10)
  • [50] EFFECT OF THE PROTEIN ARGININE METHYLTRANSFERASE PRMT5 INHIBITION IN GLIOMA STEM-LIKE CELLS
    Mittal, Sandeep
    Shaw, Vikram
    Piao, Yuji
    Park, Soon Young
    Sriram, Sai
    Dong, Jianwen
    Martinez-Ledesma, Emmanuel
    Henry, Verlene
    Ezhilarasan, Ravesanker
    Sulman, Erik
    Balasubramaniyan, Veerakumar
    de Groot, John
    NEURO-ONCOLOGY, 2018, 20 : 87 - 87
12345